 Orgenesis Inc NASDAQ:ORGS FRA:45O, the cell and gene therapies CGTs focused biotech, reported a four-fold increase in revenue in its first quarter to end-March, as the company continues its journey to build a long-term profitable business with its Point of Care POCare strategy. Revenue in the three months came in at 9.4 million, up from 1.8 million in the first quarter of 2020. 